利用不调节的铁平衡来消灭持续的高度血清性卵巢癌
Carmelo Cerra1, Madeleine R C Tancock2, Niko Thio1,3
1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Cell death discovery
|September 25, 2025
概括
高度血清性卵巢癌 (HGSOC) 细胞在初始治疗中存活,进入衰老状态. 这些衰老细胞可以通过诱导铁,一种依赖于铁水平的细胞死亡形式来根除.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 高度血清性卵巢癌 (HGSOC) 治疗通常由于残留的耐治疗细胞而失败.
- 了解治疗诱导的衰老 (TIS) 和其逃逸机制对于开发新的HGSOC治疗至关重要.
研究的目的:
- 为了研究HGSOC细胞对西斯和CX-5461/Pidnarulex的反应.
- 为了确定可以消除治疗诱导老化的HGSOC细胞的药物.
- 阐明衰老的HGSOC细胞被消灭的机制.
主要方法:
- 用西斯普拉丁和CX-5461/Pidnarulex对待HGSOC细胞.
- 分析了治疗诱导的衰老 (TIS) 标志和基因表达特征.
- 进行了聚焦的药物选,以识别老化剂.
- 机械学研究研究了铁代谢和铁灭诱导.
主要成果:
- 用化疗治疗的HGSOC细胞表现出治疗诱导衰老 (TIS) 的特征.
- 在HGSOC细胞中确定了一个核心TIS基因表达特征.
- 诱导铁亡的药物,一种依赖于铁的细胞死亡,根除了衰老的HGSOC细胞,包括对BCL-XL抑制剂耐药的细胞.
- 衰老的HGSOC细胞表现出铁代谢的改变,导致细胞内铁过载和易受铁亡的影响.
结论:
- 治疗诱导的衰老 (TIS) 是残留的HGSOC细胞的一个关键状态.
- 在衰老的HGSOC细胞中,细胞内铁含量升高代表了可准的脆弱性.
- 诱导铁亡是一种有希望的策略,在初始治疗后消除剩余的HGSOC细胞.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:07Oogenesis
69.1K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
69.1K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K